ECSP18002561A - Sales y profármacos de 1-metil-d-triptófano - Google Patents

Sales y profármacos de 1-metil-d-triptófano

Info

Publication number
ECSP18002561A
ECSP18002561A ECIEPI20182561A ECPI201802561A ECSP18002561A EC SP18002561 A ECSP18002561 A EC SP18002561A EC IEPI20182561 A ECIEPI20182561 A EC IEPI20182561A EC PI201802561 A ECPI201802561 A EC PI201802561A EC SP18002561 A ECSP18002561 A EC SP18002561A
Authority
EC
Ecuador
Prior art keywords
salts
indoximod
propharmacs
tryptophan
methyl
Prior art date
Application number
ECIEPI20182561A
Other languages
English (en)
Inventor
Hima POTTURI
Mario Mautino
Hong Zhuang
Jesse Waldo
Firoz Jaipuri
Sanjeev Kumar
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of ECSP18002561A publication Critical patent/ECSP18002561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/20—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente se proporcionan compuestos de profármacos y sales de indoximod y composiciones farmacéuticas que comprenden las sales y los profármacos de indoximod, que producen mejor concentración y exposición en plasma a indoximod en comparación con la administración directa de indoximod, en pacientes que necesitan tratamiento de inmunosupresión mediada por la vía indolamina-2,3-dioxigenasa, tales como pacientes con cáncer o enfermedades infecciosas crónicas.
ECIEPI20182561A 2015-07-24 2018-01-15 Sales y profármacos de 1-metil-d-triptófano ECSP18002561A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562196671P 2015-07-24 2015-07-24
US201662305748P 2016-03-09 2016-03-09

Publications (1)

Publication Number Publication Date
ECSP18002561A true ECSP18002561A (es) 2018-03-31

Family

ID=57836622

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20182561A ECSP18002561A (es) 2015-07-24 2018-01-15 Sales y profármacos de 1-metil-d-triptófano

Country Status (24)

Country Link
US (4) US9732035B2 (es)
EP (4) EP3324958B1 (es)
JP (4) JP6842429B2 (es)
KR (2) KR20180086300A (es)
CN (2) CN111004167B (es)
AU (1) AU2016298471C1 (es)
BR (1) BR112018000225A2 (es)
CA (3) CA2992016C (es)
CL (1) CL2018000082A1 (es)
CO (1) CO2017013724A2 (es)
CR (1) CR20180023A (es)
DO (1) DOP2018000011A (es)
EA (1) EA201792256A1 (es)
EC (1) ECSP18002561A (es)
ES (3) ES2894334T3 (es)
HK (2) HK1247837A1 (es)
IL (2) IL255625B (es)
MA (1) MA43294A1 (es)
MX (1) MX2018001014A (es)
NZ (1) NZ736978A (es)
PE (1) PE20180928A1 (es)
PH (1) PH12017502046A1 (es)
WO (1) WO2017019175A1 (es)
ZA (1) ZA201800208B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732035B2 (en) 2015-07-24 2017-08-15 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-D-tryptophan
CN109400517A (zh) * 2017-08-17 2019-03-01 上海时莱生物技术有限公司 1-甲基-色氨酸类化合物及其制备方法和用途
WO2019055786A1 (en) * 2017-09-14 2019-03-21 Lankenau Institute For Medical Research METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
CN109646683A (zh) * 2019-02-27 2019-04-19 武汉理工大学 一种1-mt-羧甲基壳聚糖药物的制备方法
CN115135385B (zh) 2019-11-12 2024-05-10 纳米医疗有限公司 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法
CN116507341A (zh) 2020-09-10 2023-07-28 纳米医疗有限公司 用于治疗癌症的含有pd-1拮抗剂前药的调配和/或共同调配的脂质体组合物及其方法
KR20250029575A (ko) 2023-08-23 2025-03-05 한국과학기술원 카메라 시스템의 동적 환경에 강인한 자기 위치 추정 장치 및 그 방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US14139A (en) 1856-01-22 Method oe ventilating railroad-cabs
GB1330573A (en) * 1970-09-12 1973-09-19 Ajinomoto Kk Optical resolution of dl-tryptophan derivatives
US4072691A (en) * 1974-01-12 1978-02-07 Tanabe Seiyaku Co., Ltd. Process for the resolution of DL-6-chlorotryptophan
US5185157A (en) * 1990-05-02 1993-02-09 Caston John C Treatment of refractory Eosinophilia-Myalgia Syndrome with L-tryptophan composition
WO1996011927A1 (en) 1994-10-12 1996-04-25 Abbott Laboratories Endothelin antagonists
US6395876B1 (en) 1997-12-05 2002-05-28 Medical College Of Georgia Research Institute, Inc. High-affinity tryptophan transporter
YU68102A (sh) * 2000-03-16 2006-01-16 F. Hoffmann-La Roche Ag. Derivati karboksilne kiseline kao ip antagonisti
US7098209B2 (en) * 2001-06-05 2006-08-29 Lilly Icos Llc Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives
CA2520172C (en) 2003-03-27 2012-10-02 Lankenau Institute For Medical Research Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
WO2005073180A1 (ja) 2003-12-25 2005-08-11 Kureha Corporation ヒドロキサム酸誘導体、及び該誘導体を含むａｇｅ生成阻害剤
PL2559690T3 (pl) 2005-05-10 2016-09-30 Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
TWI382974B (zh) 2005-12-20 2013-01-21 英塞特公司 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物
US20090155311A1 (en) * 2006-01-07 2009-06-18 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
CA2569204A1 (en) * 2006-11-28 2008-05-28 Apotex Technologies Inc. Crystalline d-isoglutamyl-d-tryptophan and the mono ammonium salt of d-isoglutamyl-d-tryptophan
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
CN101932325B (zh) 2007-11-30 2014-05-28 新联基因公司 Ido抑制剂
ATE514671T1 (de) * 2008-02-01 2011-07-15 Firmenich & Cie Substituierte cyclohexenone
CN102083429B (zh) 2008-04-24 2014-05-28 新联基因公司 Ido抑制剂
ES2524266T3 (es) 2008-07-08 2014-12-04 Incyte Corporation 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa
RS56654B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
US8722720B2 (en) * 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
CA2788284A1 (en) * 2010-02-09 2011-08-18 Georgia Health Sciences University Research Institute, Inc. Alpha-methyl-tryptophan as an inhibitor of indoleamine dioxygenase
NO2694640T3 (es) 2011-04-15 2018-03-17
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
JP2016501203A (ja) 2012-11-20 2016-01-18 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
EA201591610A1 (ru) 2013-03-14 2015-12-30 Курадев Фарма Прайвит Лтд. Ингибиторы кинуренинового пути
PE20151593A1 (es) 2013-03-14 2015-11-05 Newlink Genetics Corp Compuestos triciclicos como inhibidores de la inmunosupresion mediada por el metabolismo del triptofano
CN105324362B (zh) 2013-03-15 2017-05-24 百时美施贵宝公司 Ido抑制剂
MX2015011374A (es) 2013-03-15 2016-01-15 Squibb Bristol Myers Co Inhibidores de indolamina 2,3-dioxigenasa (ido).
JP2016528197A (ja) 2013-07-01 2016-09-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
CA2917964A1 (en) 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors
US9732035B2 (en) 2015-07-24 2017-08-15 Newlink Genetics Corporation Salts and prodrugs of 1-methyl-D-tryptophan
AU2017231817B2 (en) 2016-03-09 2021-02-25 Emory University Elimination of hepatitis B virus with antiviral agents
US10741094B2 (en) 2016-06-30 2020-08-11 Timpson Electrical & Aerial Services, LLC High voltage training device and system and method thereof

Also Published As

Publication number Publication date
US11485705B2 (en) 2022-11-01
MA43294A1 (fr) 2020-04-30
PH12017502046A1 (en) 2018-04-23
CA3051388A1 (en) 2017-02-02
ES3051614T3 (en) 2025-12-29
HK1247837A1 (zh) 2018-10-05
HK1247844A1 (zh) 2018-10-05
DOP2018000011A (es) 2018-04-30
IL268048A (en) 2019-09-26
US20180134658A1 (en) 2018-05-17
NZ736978A (en) 2019-06-28
CA3132620C (en) 2024-03-05
PE20180928A1 (es) 2018-06-08
JP2019011381A (ja) 2019-01-24
CR20180023A (es) 2018-03-20
EP4659747A2 (en) 2025-12-10
EP3324958A4 (en) 2018-10-24
KR20180030825A (ko) 2018-03-26
BR112018000225A2 (pt) 2018-09-04
US20200283385A1 (en) 2020-09-10
EP3324958B1 (en) 2021-07-28
EP3954369A1 (en) 2022-02-16
EP3613420A1 (en) 2020-02-26
CA2992016C (en) 2019-10-22
ZA201800208B (en) 2018-12-19
JP7286299B2 (ja) 2023-06-05
MX2018001014A (es) 2018-05-23
US20190248739A1 (en) 2019-08-15
ES2923184T3 (es) 2022-09-26
AU2016298471A1 (en) 2017-11-23
IL255625B (en) 2019-08-29
EP3954369B1 (en) 2025-08-20
CA2992016A1 (en) 2017-02-02
JP2018522830A (ja) 2018-08-16
CA3051388C (en) 2021-11-09
CN107847486A (zh) 2018-03-27
JP6842429B2 (ja) 2021-03-17
CN111004167B (zh) 2024-03-22
US20170022157A1 (en) 2017-01-26
EP3954369C0 (en) 2025-08-20
EA201792256A1 (ru) 2018-07-31
JP2023060349A (ja) 2023-04-27
KR20180086300A (ko) 2018-07-30
WO2017019175A1 (en) 2017-02-02
US10207990B2 (en) 2019-02-19
JP2021121633A (ja) 2021-08-26
AU2016298471B2 (en) 2019-08-22
EP3613420B1 (en) 2022-05-25
CO2017013724A2 (es) 2018-03-28
ES2894334T3 (es) 2022-02-14
CA3132620A1 (en) 2017-02-02
AU2016298471C1 (en) 2020-03-05
CN111004167A (zh) 2020-04-14
EP3324958A1 (en) 2018-05-30
IL255625A (en) 2018-01-31
US9732035B2 (en) 2017-08-15
CL2018000082A1 (es) 2018-06-15

Similar Documents

Publication Publication Date Title
DOP2018000011A (es) Sales y profármacos de 1-metil-d-triptófano
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CY1122946T1 (el) Μεθοδοι για θεραπεια filoviridαε ιου μολυνσεων
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
MX2016011038A (es) Compuestos para el tratamiento de trastornos mediados por complemento.
CO2018009382A2 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CO2017006962A2 (es) Derivados de 2-anilinopirimidina sustituida como moudladores de egfr
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
DOP2015000241A (es) Compuestos de biaril-amida como inhibidores de cinasa
MX360495B (es) Derivados deuterados de ruxolitinib.
CR20150316A (es) Compuestos y sus métodos de empleo
DOP2014000188A (es) Derivados macrocíclicos para el tratamiento de enfermedades
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
CU20160020A7 (es) Derivados de imidazoquinolinas sustituidas inhibidores de mek para el tratamiento del cáncer
DOP2017000049A (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2023012640A (es) Uso de profarmacos de riluzol para tratar ataxias.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2017003788A (es) Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial.